Glenzocimab (ACT017) is a Fab fragment of humanized anti-GPVI monoclonal antibody. Glenzocimab inhibits collagen-induced platelet aggregation. Glenzocimab has the potential for the research of acute ischemic stroke.
Purity:
>99.0%
CAS Number:
[2101829-58-5]
* VAT and and shipping costs not included. Errors and price changes excepted
